GT Biopharma, Inc. (GTBP)
$6.68+12.08%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $71M
- Beta
- 0.91
- P/E (TTM)
- -0.06
- Short % float
- 2.52%
- Days to cover
- 4.4
- SI change
- +1.1%
- 1W
- +9.51%
- 1M
- +8.09%
- vs SPY 1W
- +8.35%
- vs SPY 1M
- +5.10%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GTBP?
- LOPJLB’s latest quantitative signal on GT Biopharma, Inc. (GTBP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GTBP in?
- GT Biopharma, Inc. (GTBP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does GT Biopharma, Inc. (GTBP) do?
- GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a sin…